<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398330</url>
  </required_header>
  <id_info>
    <org_study_id>ONF16-CN-103</org_study_id>
    <nct_id>NCT03398330</nct_id>
  </id_info>
  <brief_title>OTR Tablet 40 mg Fed-state Bioequivalence Study</brief_title>
  <official_title>An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fed State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, single dose, randomized, cross-over study to confirm the bioequivalence (BE)
      of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fed state in Chinese subjects with
      chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation is designed as an open-label, single dose, randomized, and cross-over study
      to determine the pharmacokinetics(PK) profile of oxycodone from OTR tablet 40 mg and
      OXYCONTIN tablet 40 mg in Chinese subjects with chronic pain in a fed stat.

      Subjects with histories of chronic pain are chosen as the target population.
      Inclusion/exclusion criteria are strictly defined to reduce the potential variation of the PK
      data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</measure>
    <time_frame>up to 32 hours</time_frame>
    <description>The analysis was for PK parameters Cmax of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</measure>
    <time_frame>up to 32 hours</time_frame>
    <description>The analysis was for PK parameters AUCt of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</measure>
    <time_frame>up to 32 hours</time_frame>
    <description>The analysis was for PK parameters AUCINF for analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) was used to compare the test and the reference treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fed State</measure>
    <time_frame>up to 35 days</time_frame>
    <description>An overall summary of the number and percentage of Adverse Events will be provided for each treatment groups to assess the safety of OTR tablet 40 mg and OXYCONTIN® tablet 40 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lab Tests With Clinical Significance</measure>
    <time_frame>up to 35 days</time_frame>
    <description>Clinical laboratory data to be summarised includes haematology, blood chemistry, and urinalysis.Each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N) or higher than (H) the reference range for that parameter. Results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs Related to Vital Signs</measure>
    <time_frame>up to 35 days</time_frame>
    <description>Vital sign parameters to be summarised include systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature.Vital sign results for each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N), or higher than (H) the reference range for that parameter. Vital sign results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs Related to ECGs</measure>
    <time_frame>up to 35 days</time_frame>
    <description>Summarized table of 12-lead ECG is presented. ECG was measured at Screening and 4 days after IMP dosing in Period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs Related to Physical Examination</measure>
    <time_frame>up to 35 days</time_frame>
    <description>Physical examination were measured at Screening, 1 day before IMP dosing and 4 days after IMP dosing in each period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Oxycodone Tamper Resistant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxycodone Tamper Resistant (OTR) Tablet 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXYCONTIN®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OXYCONTIN® Tablet 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Tamper Resistant</intervention_name>
    <description>Orally taking Oxycodone Tamper Resistant 40mg in fed state</description>
    <arm_group_label>Oxycodone Tamper Resistant</arm_group_label>
    <other_name>Oxycodone Tamper Resistant (OTR) Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OxyContin®</intervention_name>
    <description>Orally taking OXYCONTIN® 40mg in fed state</description>
    <arm_group_label>OXYCONTIN®</arm_group_label>
    <other_name>OXYCONTIN® Tablet 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chinese male or female subjects with histories of chronic pain regardless of the
             aetiology, aged 18-55 years both inclusive

          2. The average pain over the last 24 hours should be scored &lt; 4 assessed with Numeric
             Rating Scales (NRS), when not receiving analgesics. The pain condition has been kept
             stable at least in the past 7 days prior to entering into the screening and is
             expected to be stable during the study duration

          3. Body weight ≥45 kg and a body mass index (BMI) ≥18 and ≤28 kg/m2

          4. Karnofsky score of Performance Status ≥70

          5. Willing to take all the food supplied while the subject is in the study unit

          6. Be able to read, understand, and sign written Informed Consent Form (ICF) prior to
             study participation and be willing to follow the protocol requirements

          7. Willing to use adequate and highly effective methods of contraception throughout the
             study. A highly effective method of birth control is defined as one which results in a
             low failure rate (i.e. less than 1% per year) when used consistently and correctly
             such as sterilisation, implants, injectables, some Intrauterine Device (IUD), sexual
             abstinence, or vasectomised partner

          8. Female subjects, including those up to less than one year post-menopausal, must have a
             negative serum pregnancy test and be non-lactating

        Exclusion Criteria:

          1. Subjects who are currently taking opioids or have used opioids in the past 14 days
             prior to receiving the study drug

          2. Have hypersensitivity history to any opioids, naltrexone, naloxone, or related
             compounds or any contraindications as detailed in the OTR and OXYCONTIN tablet Summary
             of Product Characteristics

          3. Histories of or any current conditions that might interfere with drug absorption,
             distribution, metabolism, or excretion

          4. Subjects who are likely to have paralytic ileus or acute abdomen or to require an
             operation on abdominal regions

          5. Subjects with biliary tract diseases, pancreatitis, prostatic hypertrophy, or
             corticoadrenal insufficiency

          6. Subjects with respiratory depression, corpulmonale, or chronic bronchial asthma

          7. Any history of seizures or symptomatic head trauma

          8. Subjects with abnormal liver function (values exceeding the upper limit of normal
             (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total
             bilirubin during the Screening Phase) or abnormal renal function (values exceeding the
             ULN for serum creatinine during the Screening Phase). Note: if the values of ALT, AST
             or total bilirubin are between 1 to 1.2 times of ULN and confirmed not clinically
             significant by the Investigators, the subject may be recruited after getting the
             approval from Sponsor.

          9. Any other significant illness other than the primary disease of chronic pain during
             the 4 weeks preceding the entry into this study

         10. Subjects who are unable to stop taking monoamine oxidase inhibitors during this trial
             period or time lapses less than 2 weeks since drug withdrawal prior to the study drug
             administration

         11. Subjects who are currently taking tricyclic antidepressants or have used tricyclic
             antidepressants within 4 weeks prior to the study drug administration

         12. Subjects who have used any medicinal product which inhibits Cytochrome P450 3A4
             (CYP3A4) (e.g. troleandomycin, ketoconazole, gestodene, etc.) or induces CYP3A4 (e.g.
             glucocorticoids, barbiturates, rifampicin, etc.) within 4 weeks prior to the study
             drug administration

         13. Subjects who have used any medicinal product which inhibits Cytochrome P450 2D6
             (CYP2D6) (e.g. fluoxetine, quinidine, ritonavir, etc.) or induces CYP2D6 (e.g.
             dexamethasone, rifampicin, glutethimide, etc.) within 4 weeks prior to the study drug
             administration

         14. Histories of smoking (being a smoker or an occasional smoker) within 45 days prior to
             the study drug administration and refusal to abstain from smoking during the study.
             According to World Health Organization (WHO), a smoker is defined as having smoked at
             least 1 cigarette per day continuously for more than 6 months and an occasional smoker
             is defined as having smoked for more than 4 times per week and less than 1 cigarette
             per day continuously for more than 6 months.

         15. Subjects with histories of alcoholism or drug abuse. Alcoholism is defined as regular
             alcohol consumption exceeding 14 drinks/week (1 drink = 150 mL of wine or 360 mL of
             beer or 45 mL of hard liquor)

         16. Consumption of alcoholic beverages within 48 hours before study drug administration,
             and refusal to abstain from alcohol for at least 48 hours after study drug
             administration

         17. Refusal to abstain from food for 10 hours preceding and 4 hours following
             administration of the study drug and to abstain from caffeine or xanthine entirely
             during each confinement

         18. Positive Hepatitis B Surface Antigen (HBsAg), anti-Hepatitis C Virus (HCV), anti-Human
             Immunodeficiency Virus (HIV), or syphilis antibody test result

         19. Urine screening before study is positive for opioids, barbiturates, amphetamines,
             cocaine metabolites, methadone, benzodiazepines, phencyclidine, methamphetamine, or
             cannabinoids. Or alcohol breath test is positive

         20. Any history of frequent nausea or emesis regardless of aetiology

         21. Blood or blood products donated within 30 days prior to administration of the study
             drugs or anytime during the study, except as required by this protocol

         22. Subjects who participated in a clinical research study within 30 days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingsheng Xu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <results_first_submitted>October 15, 2018</results_first_submitted>
  <results_first_submitted_qc>November 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2019</results_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03398330/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03398330/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>42, from Mar2017 to Sep2017, from patient database, medical clinic, advertisement recruitment and etc.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>OTR 40 Mg-OXYCONTIN 40 mg</title>
          <description>the treatment sequence is OTR 40 mg dose first and then OXYCONTIN 40 mg dose in fed state</description>
        </group>
        <group group_id="P2">
          <title>OXYCONTIN 40 Mg-OTR 40 mg</title>
          <description>the treatment sequence is OXYCONTIN 40 mg dose first and then OTR 40 mg dose in fed state</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OTR 40 Mg-OXYCONTIN 40 mg</title>
          <description>the treatment sequence is OTR 40 mg dose first and then OXYCONTIN 40 mg dose</description>
        </group>
        <group group_id="B2">
          <title>OXYCONTIN 40 Mg-OTR 40 mg</title>
          <description>the treatment sequence is OXYCONTIN 40 mg dose first and then OTR 40 mg dose in fed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="13.47"/>
                    <measurement group_id="B2" value="38.8" spread="10.12"/>
                    <measurement group_id="B3" value="37.6" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>HAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.80" spread="8.874"/>
                    <measurement group_id="B2" value="63.40" spread="9.211"/>
                    <measurement group_id="B3" value="62.10" spread="9.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.1" spread="8.25"/>
                    <measurement group_id="B2" value="162.4" spread="8.31"/>
                    <measurement group_id="B3" value="163.3" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.50" spread="2.195"/>
                    <measurement group_id="B2" value="23.95" spread="2.243"/>
                    <measurement group_id="B3" value="23.23" spread="2.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
        <description>The analysis was for PK parameters Cmax of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
        <time_frame>up to 32 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cmax of OTR Tablet 40 mg</title>
            <description>OTR Tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Cmax of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN Tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
          <description>The analysis was for PK parameters Cmax of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.15" lower_limit="67.895" upper_limit="104.405"/>
                    <measurement group_id="O2" value="63.54" lower_limit="50.035" upper_limit="77.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
        <description>The analysis was for PK parameters AUCt of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
        <time_frame>up to 32 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AUCt of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>AUCt of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
          <description>The analysis was for PK parameters AUCt of analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) were used to compare the test and the reference treatments.</description>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641.3017" lower_limit="517.97802" upper_limit="764.62538"/>
                    <measurement group_id="O2" value="646.2133" lower_limit="514.12207" upper_limit="778.30453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
        <description>The analysis was for PK parameters AUCINF for analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) was used to compare the test and the reference treatments.</description>
        <time_frame>up to 32 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AUCINF of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>AUCINF of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State</title>
          <description>The analysis was for PK parameters AUCINF for analyte oxycodone. Analysis of Variance (ANOVA) with fixed effect terms for treatment, period, sequence, and subject within sequence for ratio of means (using log scale) was used to compare the test and the reference treatments.</description>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.2546" lower_limit="521.43808" upper_limit="775.07112"/>
                    <measurement group_id="O2" value="664.0493" lower_limit="521.26837" upper_limit="806.8302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fed State</title>
        <description>An overall summary of the number and percentage of Adverse Events will be provided for each treatment groups to assess the safety of OTR tablet 40 mg and OXYCONTIN® tablet 40 mg.</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adverse Events of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Adverse Events of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fed State</title>
          <description>An overall summary of the number and percentage of Adverse Events will be provided for each treatment groups to assess the safety of OTR tablet 40 mg and OXYCONTIN® tablet 40 mg.</description>
          <units>TEAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of AEs (#)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of TEAEs (#)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of relateda TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lab Tests With Clinical Significance</title>
        <description>Clinical laboratory data to be summarised includes haematology, blood chemistry, and urinalysis.Each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N) or higher than (H) the reference range for that parameter. Results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Laboratory Data of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Clinical Laboratory Data of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lab Tests With Clinical Significance</title>
          <description>Clinical laboratory data to be summarised includes haematology, blood chemistry, and urinalysis.Each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N) or higher than (H) the reference range for that parameter. Results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
          <units>Lab tests with clinical significance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of AEs Related to Vital Signs</title>
        <description>Vital sign parameters to be summarised include systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature.Vital sign results for each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N), or higher than (H) the reference range for that parameter. Vital sign results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vital Signs of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Vital Signs of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of AEs Related to Vital Signs</title>
          <description>Vital sign parameters to be summarised include systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature.Vital sign results for each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N), or higher than (H) the reference range for that parameter. Vital sign results will be summarised using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, and higher than).</description>
          <units>AEs of vital signs related</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of AEs Related to ECGs</title>
        <description>Summarized table of 12-lead ECG is presented. ECG was measured at Screening and 4 days after IMP dosing in Period 2.</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ECG of OTR Tablet 40 mg</title>
            <description>OTR tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>ECG of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of AEs Related to ECGs</title>
          <description>Summarized table of 12-lead ECG is presented. ECG was measured at Screening and 4 days after IMP dosing in Period 2.</description>
          <units>AEs of ECG related</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of AEs Related to Physical Examination</title>
        <description>Physical examination were measured at Screening, 1 day before IMP dosing and 4 days after IMP dosing in each period.</description>
        <time_frame>up to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Examination of OTR Tablet 40 mg</title>
            <description>OTR Tablet 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Physical Examination of OXYCONTIN Tablet 40 mg</title>
            <description>OXYCONTIN Tablet 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of AEs Related to Physical Examination</title>
          <description>Physical examination were measured at Screening, 1 day before IMP dosing and 4 days after IMP dosing in each period.</description>
          <units>AEs related to Physical examination</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events will be recorded from the point at which the ICF is signed until 7±1 days after last oxycodone dose in the case of completion/discontinuation from the study. This includes new AEs that are reported within 7±1 days after last oxycodone dosing after the subject's completion/discontinuation visit.</time_frame>
      <desc>same with clinicaltrials.gov Definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>OTR 40mg</title>
          <description>Oxycodone Tamper Resistant (OTR) Tablet 40 mg
Oxycodone Tamper Resistant: Orally taking Oxycodone Tamper Resistant 40mg in fed state</description>
        </group>
        <group group_id="E2">
          <title>OXYCONTIN® 40mg</title>
          <description>OXYCONTIN® Tablet 40 mg
OxyContin®: Orally taking OXYCONTIN® 40mg in fed state</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rongna. A</name_or_title>
      <organization>Mundipharma(China) Pharmaceutical. Co. Ltd</organization>
      <phone>86 10 65636885</phone>
      <email>rongna.a@mundipharma.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

